Pyxis Oncology Appoints Alex Kane as Senior Vice President, Investor Relations & Capital Markets
Provided By GlobeNewswire
Last update: Oct 9, 2025
BOSTON, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing antibody-drug conjugate (ADC) therapeutics for difficult-to-treat cancers, today announced the appointment of Alex Kane, MBA, as Senior Vice President, Investor Relations & Capital Markets, effective immediately.
Read more at globenewswire.com
